Heron Therapeutics Inc vs Neurocrine Biosciences Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $61.47M), while Neurocrine Biosciences Inc trades at $151.75 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 267.8× Heron Therapeutics Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | NBIX | |
|---|---|---|
Market Cap | $61.47M | $16.46B |
Sector | Health | Health |
52-Week High | $1.49 | $185.50 |
52-Week Low | $0.32 | $123.10 |
Enterprise Value | $168.21M | $16.48B |
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →